426 related articles for article (PubMed ID: 33757321)
1. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.
Pelletier R
J Oncol Pharm Pract; 2021 Jun; 27(4):911-918. PubMed ID: 33757321
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer.
Parker A; Peterson E; Lee AYY; de Wit C; Carrier M; Polley G; Tien J; Wu C
J Thromb Haemost; 2018 Jul; 16(7):1321-1326. PubMed ID: 29733498
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
[TBL] [Abstract][Full Text] [Related]
4. Successful Model for Guideline Implementation to Prevent Cancer-Associated Thrombosis: Venous Thromboembolism Prevention in the Ambulatory Cancer Clinic.
Holmes CE; Ades S; Gilchrist S; Douce D; Libby K; Rogala B; Parenteau E; Cushman M; Holm AK
JCO Oncol Pract; 2020 Sep; 16(9):e868-e874. PubMed ID: 32267798
[TBL] [Abstract][Full Text] [Related]
5. [Thromboprophylaxis in ambulatory patients with cancer].
Hart C; Heudobler D; Linnemann B
Dtsch Med Wochenschr; 2020 Feb; 145(3):130-134. PubMed ID: 32018283
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
7. Pharmacist-led program to improve venous thromboembolism prophylaxis in a community hospital.
Bauer JB; Chun DS; Karpinski TA
Am J Health Syst Pharm; 2008 Sep; 65(17):1643-7. PubMed ID: 18714111
[TBL] [Abstract][Full Text] [Related]
8. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study.
Cella CA; Di Minno G; Carlomagno C; Arcopinto M; Cerbone AM; Matano E; Tufano A; Lordick F; De Simone B; Muehlberg KS; Bruzzese D; Attademo L; Arturo C; Sodano M; Moretto R; La Fata E; De Placido S
Oncologist; 2017 May; 22(5):601-608. PubMed ID: 28424324
[TBL] [Abstract][Full Text] [Related]
9. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.
Muñoz A; Ay C; Grilz E; López S; Font C; Pachón V; Castellón V; Martínez-Marín V; Salgado M; Martínez E; Calzas J; Ortega L; Rupérez A; Salas E; Pabinger I; Soria JM
J Clin Oncol; 2023 Jun; 41(16):2911-2925. PubMed ID: 36730884
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for cancer-associated venous thromboembolism: The venous thromboembolism prevention in the ambulatory cancer clinic (VTE-PACC) study.
Douce DR; Holmes CE; Cushman M; MacLean CD; Ades S; Zakai NA
J Thromb Haemost; 2019 Dec; 17(12):2152-2159. PubMed ID: 31423717
[TBL] [Abstract][Full Text] [Related]
11. [Predicting the Incidence of Venous Thromboembolism Using the Khorana Score: A Literature Review].
Nishimura A; Ikeda Y
Yakugaku Zasshi; 2021; 141(4):611-622. PubMed ID: 33790126
[TBL] [Abstract][Full Text] [Related]
12. Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy.
Overvad TF; Ording AG; Nielsen PB; Skjøth F; Albertsen IE; Noble S; Vistisen AK; Gade IL; Severinsen MT; Piazza G; Larsen TB
Blood Adv; 2022 May; 6(10):2967-2976. PubMed ID: 35045569
[TBL] [Abstract][Full Text] [Related]
13. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis.
van Es N; Ventresca M; Di Nisio M; Zhou Q; Noble S; Crowther M; Briel M; Garcia D; Lyman GH; Macbeth F; Griffiths G; Iorio A; Mbuagbaw L; Neumann I; Brozek J; Guyatt G; Streiff MB; Baldeh T; Florez ID; Gurunlu Alma O; Agnelli G; Ageno W; Marcucci M; Bozas G; Zulian G; Maraveyas A; Lebeau B; Lecumberri R; Sideras K; Loprinzi C; McBane R; Pelzer U; Riess H; Solh Z; Perry J; Kahale LA; Bossuyt PM; Klerk C; Büller HR; Akl EA; Schünemann HJ;
J Thromb Haemost; 2020 Aug; 18(8):1940-1951. PubMed ID: 32336010
[TBL] [Abstract][Full Text] [Related]
14. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis.
Li A; Kuderer NM; Garcia DA; Khorana AA; Wells PS; Carrier M; Lyman GH
J Thromb Haemost; 2019 Dec; 17(12):2141-2151. PubMed ID: 31420937
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients.
Schorling RM; Pfrepper C; Golombek T; Cella CA; Muñoz-Unceta N; Siegemund R; Engel C; Petros S; Lordick F; Knödler M
Oncol Res Treat; 2020; 43(9):414-427. PubMed ID: 32580190
[TBL] [Abstract][Full Text] [Related]
16. Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy.
Kandemir EA; Bayraktar-Ekincioglu A; Kilickap S
Support Care Cancer; 2021 Mar; 29(3):1699-1709. PubMed ID: 32776163
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer.
Guman NAM; van Geffen RJ; Mulder FI; van Haaps TF; Hovsepjan V; Labots M; Cirkel GA; Y F L de Vos F; Ten Tije AJ; Beerepoot LV; Tjan-Heijnen VCG; van Laarhoven HWM; Hamberg P; Vulink AJE; Los M; Zwinderman AH; Ferwerda B; Lolkema MPJK; Steeghs N; Büller HR; Kamphuisen PW; van Es N
J Thromb Haemost; 2021 Dec; 19(12):2974-2983. PubMed ID: 34409743
[TBL] [Abstract][Full Text] [Related]
18. Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis.
Bosch FTM; Mulder FI; Kamphuisen PW; Middeldorp S; Bossuyt PM; Büller HR; van Es N
Blood Adv; 2020 Oct; 4(20):5215-5225. PubMed ID: 33104795
[TBL] [Abstract][Full Text] [Related]
19. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial.
Kimpton M; Wells PS; Carrier M
Thromb Res; 2018 Apr; 164 Suppl 1():S124-S129. PubMed ID: 29703470
[TBL] [Abstract][Full Text] [Related]
20. Comparison among three predictive models for cancer-associated thromboembolism in a hispanic population.
Ramos-Esquivel A; Marenco-Flores A; Hernández-Romero G; Céspedes-Calvo A; Mora-Hidalgo R
J Thromb Thrombolysis; 2023 Oct; 56(3):433-438. PubMed ID: 37407771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
